CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
LY3502970drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05313802
NCT05313802Phase 1Completed
CompareCT.gov

A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970

Eli Lilly and Company·interventional·Posted Apr 6, 2022·Updated May 26, 2026

In Brief

A Phase 1 clinical trial evaluating LY3502970 for Healthy and Obese. Completed, enrolled 72 participants across 3 sites.

Detailed Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Obese
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedApr 6, 2022
Enrollment StartMay 26, 2022
Primary CompletionSep 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.2 years ago

Interventions

LY3502970drug

Administered orally.